A group of drugs, including, apixiban, edoxaban and rivaroxaban which have the apparent advantage of not requiring repeated blood monitoring to guard against under- or over-dose. Consequently they are used increasingly in preventing stroke in patients with the ARRHYTHMIA atrial fibrillation.